Caution of retinal toxicity using chloroquine and hydroxychloroquine in the treatment of COVID-19
10.3980/j.issn.1672-5123.2020.7.39
- VernacularTitle:应用氯喹和羟氯喹治疗新型冠状病毒肺炎需警惕视网膜毒性
- Author:
Li-Yuan Wang
1
Author Information
1. Department of Ophthalmology, First Affiliated Hospital of Heilongjiang University of Chinese Medicine, Harbin 150040, Heilongjiang Province, China
- Publication Type:Journal Article
- Keywords:
chloroquine;
hydroxychloroquine;
COVID-19;
retinal toxicity
- From:International Eye Science
2020;20(7):1290-1294
- CountryChina
- Language:Chinese
-
Abstract:
“Chloroquine phosphate” was listed as a trial drug in diagnosis and treatment program of COVID-19(trial sixth edition), and the application of chloroquine and hydroxychloroquine treatment for COVID-19 in medical institutions also increased. Chloroquine and hydroxychloroquine have certain retinal toxicity, its mechanism is still unclear, due to different drug tolerance, the risk degree of retinal toxicity in COVID-19 treatment is unclear. Therefore, when using chloroquine and hydroxychloroquine in the treatment of COVID-19, it is recommended to choose the appropriate dosage according to patients' situation, and adopt necessary ophthalmic screening for patients with high risk to prevent the occurrence of retinopathy. In this paper, we described the risk factors, clinical manifestations and screening methods of retinal toxicity caused by chloroquine and hydroxychloroquine, in order to provide references for the safer use of chloroquine and hydroxychloroquine in the treatment of COVID-19.
- Full text:202007039.pdf
